• Introduction

    Since its inception in 2013, CIIC had a unanimous consensus that clinical research should be a major part of the CIIC mission in trying to better the lives of our patients.  Immunology is in the fore front of scientific research and innovations which have lead to numerous achievements in many fields in medicine and in particular in immunology, both in diagnostics and treatments.    By far PIDD have lead to our understanding and exploring further the field of immunology.  Many of our members have a significant experience, both in clinical and bench research in the field of immunology and we believe that as a group we can combine forces and participate primarily in clinical research to further understand PIDD, and engage in evaluating therapeutic solutions with the main goal to improve the life of our patients with PIDD.

  • Patient Registry Project

    Very quickly we realized that in order for us to engage in clinical research in PIDD, we need to create a Patient Registry of our PIDD patients under our care.  We have estimated that 3,400 PIDD patients are currently being taken care by our 17 CIIC clinic members at the present time.  We have established a CIIC Patient Registry on a secure platform and so far populated more than 1,250 patients.  The Patient Registry was developed by our CIIC Immunology expert members with the idea to incorporate all necessary basic diagnostic and clinical information, including more than 250 field items, to better characterize PIDD and identify potential patients of interest for clinical studies.   The project received IRB approval and currently 17 CIIC clinic members participate in it.

  • Genetic Study

    Genetic diagnosis have gained tremendous interest in the last two decades in medicine and in particular in congenital medical conditions.  PIDD, by definition, are medial conditions due to genetic causes.  Genetic studies have contributed tremendously to our understanding of PIDD and to develop innovative, life saving therapeutic solutions.  Even though many cases of PIDD were identified genetically, genetic diagnosis is primarily the domain of research and is poorly covered by insurance companies in clinical routine.  Genetic diagnosis of PIDD is necessary to identify the specific genetic cause in order to implement the best existing therapeutic solutions.  The CIIC has teamed up –with Seattle Children’s Immunology Institute, under the direction of Dr. Troy Torgerson and Dr. Hans Ochs, to evaluate genetically 500 selected cases of PIDD in trying to establish the validity and importance of genetic testing of PIDD patients.  We have secured funding from the Pharmaceutical industry and obtained their generous support (Green Cross Corp, Shire/Takeda, Soleo Health) and obtained IRB approval for the project.

    Merited cases identified from the CIIC Patient Registry constitute is the source for patient recruitment.  So far more than 40 patients were identified and evaluated.  We estimate  completing patient recruitment within the next 18 months.

  • Advisory Board

    Our initial research activities as a group was to help key pharmaceutical companies involved in the various treatment solutions of PIDD as an expert advisory group in particular projects.  Such projects included developing guidelines for the standard of care of Immunoglobulin products administered subcutaneously (HyQvia) or intravenously (Octagam).

  • Clinical Studies

    As a cohesive group of experienced immunologists who have participated in numerous clinical studies in the past (both together as a group and as individual co-investigators), the CIIC Patient Registry, and our Research Management Team, we have the ability to provide interested Sponsors in Phase II/III  clinical studies, substantial advantages to conduct high quality clinical studies in a timely manner while providing substantial savings to such sponsors.  We have in place an experienced Research Management Team, with up to date credential documents of all CIIC members/co-investigators and their clinics, and the ability to identify consenting patients of interest from our Patient Registry according to specific sets of exclusion/inclusion criteria.  As a group we have accomplished together such clinical studies in the past while negotiating as a group, providing all necessary patients to the study project, and helped managed the study in close cooperation with the designated CRO.   We were able to accomplish the study projects in a timely manner and provided substantial savings to the Sponsor, compared to the conventional way such studies have been conducted at present.